Neuroone Medical Technologies Corporation
08/18/2025 | Press release | Distributed by Public on 08/18/2025 06:42
Material Event (Form 8-K)
Item 8.01 Other Events.
On August 18, 2025, NeuroOne Medical Technologies Corporation announced that it has received U.S. Food and Drug Administration 510(k) clearance to market its OneRF® Trigeminal Nerve Ablation System for use in procedures to create radiofrequency lesions for the treatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures.
Neuroone Medical Technologies Corporation published this content on August 18, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on August 18, 2025 at 12:42 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]